Carboxyamidotriazole orotate in combination with temozolomide, with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma or anaplastic gliomas.
The NCCN has added the combination of TTFields (Optune) and temozolomide (Temodar) to its guidelines for Category 1 treatment of newly diagnosed glioblastoma following maximal safe resection and completion of radiation therapy.
Investigators are seeking to determine whether the combination of eflornithine with lomustine can improve survival for patients with recurrent anaplastic astrocytoma.
Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment.
Adding tumor-treating fields to temozolomide resulted in improved progression-free survival and overall survival for patients with glioblastoma.
A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.
The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.
Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.
The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.
In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).